Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 12/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 9/20 | 0.34 |
| ▸ | ASGR1 | P07306 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19510143 | 1.00 | SLC5A2 (0.36) | SLC5A2SLC5A1ASGR1 | |
| SCHEMBL22459100 | 1.00 | SLC5A2 (0.36) | SLC5A2SLC5A1ASGR1 | |
| SCHEMBL19510142 | 1.00 | SLC5A2 (0.36) | SLC5A2SLC5A1ASGR1 | |
| SCHEMBL5129151 | 0.73 | ASGR1 (0.30) | ASGR1 | |
| SCHEMBL15216212 | 0.68 | ASGR1 (0.41) | SLC5A2SLC5A1ASGR1 | |
| SCHEMBL11296106 | 0.68 | ASGR1 (0.41) | SLC5A2SLC5A1ASGR1 | |
| SCHEMBL11297839 | 0.68 | ASGR1 (0.41) | SLC5A2SLC5A1ASGR1 | |
| SCHEMBL24849981 | 0.65 | SLC5A2 (0.36) | SLC5A2SLC5A1ASGR1 | |
| SCHEMBL8781339 | 0.59 | KMT2A (0.32) | — | |
| SCHEMBL22497371 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10500186-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20190142793-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10500186-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ASGR1 826/4885 |
| US-20190142793-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ASGR1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.